OASIS-6 (Sixth Organization to AssessStrategies in Acute Ischemic Syndromes)
OASIS-6 (Sixth Organization to Assess Strategies inAcute Ischemic Syndromes)S Yusuf (McMaster University, Hamilton, ON)Ame...
OASIS-6: Results• Fondaparinux significantly reduced the primary efficacy end point• There was no heterogeneity of the eff...
OASIS-6: Commentary*"I might . . . use fondaparinux for patients who are not going to get a PCI. It doesseem to have a ble...
Become a member of http://www.theheart.org    Become a fan on Facebook: http://www.facebook.com/theheartorg          Follo...
Upcoming SlideShare
Loading in …5
×

OASIS-6 trial - Summary & Results at ACC

858 views

Published on

http://www.theheart.org/web_slides/1136801.do

A randomized, placebo study using patients with STEMI exposed to fondaparinux or to usual care-placebo. The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes.

Published in: Health & Medicine, Technology
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
858
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
23
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

OASIS-6 trial - Summary & Results at ACC

  1. 1. OASIS-6 (Sixth Organization to AssessStrategies in Acute Ischemic Syndromes)
  2. 2. OASIS-6 (Sixth Organization to Assess Strategies inAcute Ischemic Syndromes)S Yusuf (McMaster University, Hamilton, ON)American College of Cardiology 2006 Scientific Sessions• Background: There is a need for an effective, inexpensive, and safe antithrombotic agent for patients with STEMI• Population and treatment: 12 092 patients with STEMI were randomized to fondaparinux (2.5 mg once daily given for up to eight days) or usual care—placebo for those in whom UFH was not indicated (stratum 1) or UFH for up to 48 hours followed by placebo for up to eight days (stratum 2)• Primary outcome: A composite of death or reinfarction at 30 daysUFH=unfractionated heparin
  3. 3. OASIS-6: Results• Fondaparinux significantly reduced the primary efficacy end point• There was no heterogeneity of the effects of fondaparinux in the two strata by planned heparin use• There was no benefit in the 3789 patients who underwent primary PCIPrimary end pointTime point Fondaparinux Control HR (95% CI) p (n=6036), % (n=6056), %30 days (primary end point) 9.7 11.2 0.86 (0.77–0.96) 0.0089 days 7.4 8.9 0.83 (0.73–0.94) 0.0033–6 months 13.4 14.8 0.88 (0.79–0.97) 0.008
  4. 4. OASIS-6: Commentary*"I might . . . use fondaparinux for patients who are not going to get a PCI. It doesseem to have a bleeding advantage, but I will reserve judgment until I see a bettercut of the data." - Dr Paul Armstrong"In the absence of any further specific information from OASIS-6 about exactly whodid or did not receive any attempt at reperfusion (primary PCI, fibrinolytic), how itwas supported (placebo, unfractionated heparin, or fondaparinux), and exactly howlong patients were followed—it is hard to incorporate the information onfondaparinux in the enlarging array of treatment options for managing STEMIpatients." - Dr Elliott Antman *All comments from Experts clash over relative benefits of enoxaparin and fondaparinux in EXTRACT-TIMI 25 and OASIS-6 (http://www.theheart.org/article/674653.do)
  5. 5. Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorgtheheart.org is the leading online source of independent cardiology news.We are the top provider of news and opinions for over 100 000 physicians.

×